KR100634847B1 - 췌장도 조직 이식을 위한 ｃｄ154 차단 요법 - Google Patents

췌장도 조직 이식을 위한 ｃｄ154 차단 요법 Download PDF

Info

Publication number
KR100634847B1
KR100634847B1 KR1019997011991A KR19997011991A KR100634847B1 KR 100634847 B1 KR100634847 B1 KR 100634847B1 KR 1019997011991 A KR1019997011991 A KR 1019997011991A KR 19997011991 A KR19997011991 A KR 19997011991A KR 100634847 B1 KR100634847 B1 KR 100634847B1
Authority
KR
South Korea
Prior art keywords
tissue
receptor
agent
delete delete
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997011991A
Other languages
English (en)
Korean (ko)
Other versions
KR20010013965A (ko
Inventor
케년노르마에스
리코르디카밀로
토마스데이비드더블유
버클리린다
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
유니버시티 오브 마이애미
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드, 유니버시티 오브 마이애미 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20010013965A publication Critical patent/KR20010013965A/ko
Application granted granted Critical
Publication of KR100634847B1 publication Critical patent/KR100634847B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
KR1019997011991A 1997-06-20 1998-06-19 췌장도 조직 이식을 위한 ｃｄ154 차단 요법 Expired - Fee Related KR100634847B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US60/050,267 1997-06-20
US7726598P 1998-03-09 1998-03-09
US60/077,265 1998-03-09
PCT/US1998/012892 WO1998058669A2 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for pancreatic islet tissue transplantation

Publications (2)

Publication Number Publication Date
KR20010013965A KR20010013965A (ko) 2001-02-26
KR100634847B1 true KR100634847B1 (ko) 2006-10-17

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997011991A Expired - Fee Related KR100634847B1 (ko) 1997-06-20 1998-06-19 췌장도 조직 이식을 위한 ｃｄ154 차단 요법

Country Status (21)

Country Link
US (2) US20030072754A1 (enExample)
EP (1) EP1051191B1 (enExample)
JP (1) JP2002506446A (enExample)
KR (1) KR100634847B1 (enExample)
CN (2) CN1651919A (enExample)
AT (1) ATE339966T1 (enExample)
AU (1) AU730763B2 (enExample)
BG (1) BG64976B1 (enExample)
BR (1) BR9810620A (enExample)
CA (1) CA2294154A1 (enExample)
DE (1) DE69835965T2 (enExample)
EA (1) EA002550B1 (enExample)
EE (1) EE9900588A (enExample)
HU (1) HUP0003160A3 (enExample)
IL (1) IL133303A0 (enExample)
IS (1) IS5273A (enExample)
NO (1) NO996275L (enExample)
NZ (1) NZ502052A (enExample)
SK (1) SK180299A3 (enExample)
TR (1) TR199903142T2 (enExample)
WO (1) WO1998058669A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773176B2 (en) 2020-01-24 2023-10-03 Aprilbio Co., Ltd. Multispecific antibodies, compositions comprising the same, and vectors and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
EP1814980B1 (en) * 2004-11-22 2015-03-25 Ramot at Tel-Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
WO2010093467A1 (en) * 2009-02-10 2010-08-19 The Trustees Of Columbia University In The City Of New York Methods for inducing transplantation tolerance
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
DE69713499T3 (de) * 1996-03-20 2010-05-06 Bristol-Myers Squibb Co., Seattle Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773176B2 (en) 2020-01-24 2023-10-03 Aprilbio Co., Ltd. Multispecific antibodies, compositions comprising the same, and vectors and uses thereof

Also Published As

Publication number Publication date
DE69835965T2 (de) 2007-06-14
WO1998058669A3 (en) 1999-04-29
AU7983098A (en) 1999-01-04
US20070292440A1 (en) 2007-12-20
HUP0003160A3 (en) 2002-09-30
BG104091A (en) 2000-10-31
WO1998058669A2 (en) 1998-12-30
NZ502052A (en) 2001-01-26
SK180299A3 (en) 2000-06-12
NO996275L (no) 2000-02-21
NO996275D0 (no) 1999-12-17
AU730763B2 (en) 2001-03-15
BR9810620A (pt) 2000-10-03
JP2002506446A (ja) 2002-02-26
CA2294154A1 (en) 1998-12-30
IS5273A (is) 1999-11-26
EA200000058A1 (ru) 2000-08-28
ATE339966T1 (de) 2006-10-15
TR199903142T2 (xx) 2000-09-21
BG64976B1 (bg) 2006-11-30
CN1195546C (zh) 2005-04-06
EP1051191B1 (en) 2006-09-20
US20030072754A1 (en) 2003-04-17
EE9900588A (et) 2000-08-15
CN1651919A (zh) 2005-08-10
IL133303A0 (en) 2001-04-30
HK1033548A1 (en) 2001-09-07
EP1051191A2 (en) 2000-11-15
DE69835965D1 (de) 2006-11-02
HUP0003160A2 (hu) 2001-01-29
CN1261286A (zh) 2000-07-26
KR20010013965A (ko) 2001-02-26
EA002550B1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
KR100634847B1 (ko) 췌장도 조직 이식을 위한 ｃｄ154 차단 요법
KR100575069B1 (ko) 역적응성 면역 반응, 특히 이식 거부반응을 예방하기 위한ｃｄ40:ｃｄ154 결합 저해제의 용도
US20030170239A1 (en) Immunotherapeutic method to prevent islet cell rejection
EP1754490A2 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
HK1033548B (en) Cd154 blockade therapy for pancreatic islet tissue transplantation in primates
CZ461699A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín
PL191122B1 (pl) Zastosowania przerywacza wiązania CD40:CD154
MXPA99011740A (en) Cd154 blockade therapy for pancreatic islet tissue transplantation
WO1999045958A1 (en) Cd154 blockade therapy for modulation of immune responses to implanted devices
CN1736483A (zh) 应用cd40：cd154结合阻断物预防反适应性免疫应答,特别是移植物排斥反应
CZ403599A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro výrobu léku k inhibici odhojení tkáňového štěpu a přípravek obsahující činidlo rušící vazbu CD40:CD154
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
CA2276733A1 (en) Methods and compositions for preventing autoimmune disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091011

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091011

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000